The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC).
 
Denise A. Yardley
No Relationships to Disclose
 
Linda D. Bosserman
Employment - Wilshire Oncology Medical Group, inc.
Leadership - Anthem Blue Cross Wellpoint; Prime Care Inland Valley
Honoraria - Genentech; Pfizer
Consulting or Advisory Role - Dendreon; Genentech/Roche; GlaxoSmithKline; Pfizer; Pfizer
Speakers' Bureau - Pfizer
 
Mark Robert Keaton
No Relationships to Disclose
 
Mary Audrey Ackerman
No Relationships to Disclose
 
Sharon A. Goble
No Relationships to Disclose
 
Dianna Shipley
No Relationships to Disclose
 
Emile Salloum
No Relationships to Disclose
 
William N. Harwin
Consulting or Advisory Role - Axess Oncology; Oncology Reimbursement Manager; Research to Practice
Research Funding - Sarah Cannon Research Institute
 
Brooke R. Daniel
No Relationships to Disclose
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
Howard A. Burris
No Relationships to Disclose